

Full list of references

- 1 Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet (London, England)* 2017;**390**:1345-422.
- 2 Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. *European heart journal* 2003;**24**:442-63.
- 3 Kajimoto K, Sato N, Takano T. Relation of left ventricular ejection fraction and clinical features or co-morbidities to outcomes among patients hospitalized for acute heart failure syndromes. *The American journal of cardiology* 2015;**115**:334-40.
- 4 Nichols GA, Reynolds K, Kimes TM, et al. Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. *The American journal of cardiology* 2015;**116**:1088-92.
- 5 Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *Journal of the American College of Cardiology* 2012;**59**:998-1005.
- 6 Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet (London, England)* 2002;**360**:1903-13.
- 7 Lip GY, Skjoth F, Overvad K, et al. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. *Clinical research in cardiology : official journal of the German Cardiac Society* 2015;**104**:1088-96.

- 8 Schmid FA, Schlager O, Keller P, et al. Prognostic value of long-term blood pressure changes in patients with chronic heart failure. *European journal of heart failure* 2017;**19**:837-42.
- 9 Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. *Heart (British Cardiac Society)* 2009;**95**:56-62.
- 10 Desai RV, Banach M, Ahmed MI, et al. Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). *The American journal of cardiology* 2010;**106**:221-7.
- 11 Bohm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. *European heart journal* 2017;**38**:1132-43.
- 12 Ather S, Chan W, Chillar A, et al. Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. *American heart journal* 2011;**161**:567-73.
- 13 Messerli FH, Rimoldi SF, Bangalore S. The Transition From Hypertension to Heart Failure: Contemporary Update. *JACC Heart failure* 2017;**5**:543-51.
- 14 Ather S, Bangalore S, Vemuri S, et al. Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. *The American journal of cardiology* 2011;**107**:561-8.
- 15 Tsujimoto T, Kajio H. Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction. *International journal of cardiology* 2018.

- 16 Tsimploulis A, Lam PH, Arundel C, et al. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. *JAMA cardiology* 2018.
- 17 Xie W, Zheng F, Evangelou E, et al. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. *Journal of hypertension* 2018.
- 18 Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. *Journal of hypertension* 2007;**25**:951-8.
- 19 Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. *Bmj* 2003;**326**:1427.
- 20 Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet (London, England)* 1999;**353**:2001-7.
- 21 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *New England Journal of Medicine* 1996;**334**:1349-55.
- 22 Sakata Y, Shiba N, Takahashi J, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. *European heart journal* 2015;**36**:915-23.
- 23 Levine TB, Bernink PJ, Caspi A, et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial. *Circulation* 2000;**101**:758-64.

- 24 Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. *American heart journal* 2000;**139**:503-10.
- 25 Cohn JN, Archibald DG, Ziesche S. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. *New England Journal of Medicine* 1986;**314**:1547-52.
- 26 Bazoukis G, Thomopoulos C, Tse G, et al. Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. *Heart failure reviews* 2018.
- 27 Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. *Journal of hypertension* 2018;**36**:987-94.
- 28 Weber T, Chirinos JA. Pulsatile arterial haemodynamics in heart failure. *European heart journal* 2018;**39**:3847-54.
- 29 Regnault V, Lagrange J, Pizard A, et al. Opposite predictive value of pulse pressure and aortic pulse wave velocity on heart failure with reduced left ventricular ejection fraction: insights from an Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) substudy. *Hypertension (Dallas, Tex : 1979)* 2014;**63**:105-11.
- 30 Meguro T, Nagatomo Y, Nagae A, et al. Elevated arterial stiffness evaluated by brachial-ankle pulse wave velocity is deleterious for the prognosis of patients with heart failure. *Circ J* 2009;**73**:673-80.
- 31 Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed

with the special contribution of the Heart Failure Association (HFA) of the ESC. *European journal of heart failure* 2016;**18**:891-975.

32 Chi G, Jamil A, Jamil U, et al. Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials. *Clinical and experimental hypertension (New York, NY : 1993)* 2018;1-8.

33 Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. *Lancet (London, England)* 2017;**389**:2226-37.

34 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *European heart journal* 2018;**39**:3021-104.

35 Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. *The Canadian journal of cardiology* 2018;**34**:506-25.

36 Meredith PA, Ostergren J, Anand I, et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. *Journal of the American College of Cardiology* 2008;**52**:2000-7.

37 Selvaraj S, Claggett B, Shah SJ, et al. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. *European journal of heart failure* 2018;**20**:483-90.

38 Abdul-Rahim AH, Perez AC, MacIsaac RL, et al. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. *European heart journal* 2017;**38**:742-50.

- 39 McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet (London, England)* 2003;**362**:767-71.
- 40 Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet (London, England)* 2002;**359**:995-1003.
- 41 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Jama* 2002;**288**:2981-97.
- 42 Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet (London, England)* 2004;**363**:2022-31.
- 43 Hsu JJ, Ziaeian B, Fonarow GC. Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions. *JACC Heart failure* 2017;**5**:763-71.
- 44 Nauta JF, Hummel YM, van Melle JP, et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? *European journal of heart failure* 2017;**19**:1569-73.
- 45 Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *European heart journal* 2014;**35**:2797-815.
- 46 Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. *Circulation* 2011;**123**:2006-13; discussion 14.

- 47 De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. *Circulation* 2011;**123**:1996-2004; discussion 5.
- 48 Dunlay SM, Roger VL, Weston SA, et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. *Circulation Heart failure* 2012;**5**:720-6.
- 49 Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. *Heart (British Cardiac Society)* 2018;**104**:377-84.
- 50 Bloom MW, Greenberg B, Jaarsma T, et al. Heart failure with reduced ejection fraction. *Nature reviews Disease primers* 2017;**3**:17058.
- 51 Solomon SD, Claggett B, Desai AS, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. *Circulation Heart failure* 2016;**9**:e002744.
- 52 Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *The New England journal of medicine* 2011;**364**:11-21.
- 53 Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *The New England journal of medicine* 2014;**370**:1383-92.
- 54 Solomon SD, Claggett B, Lewis EF, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. *European heart journal* 2016;**37**:455-62.
- 55 Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *European heart journal* 2013;**34**:1404-13.

- 56 Anand IS, Rector TS, Kuskowski M, et al. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. *Circulation Heart failure* 2008;**1**:34-42.
- 57 Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. *Journal of the American College of Cardiology* 2007;**49**:32-9.
- 58 Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. *Nature reviews Cardiology* 2017;**14**:30-8.
- 59 Chrysant SG, Chrysant GS. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls. *Current hypertension reports* 2015;**17**:511.
- 60 Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *European journal of heart failure* 2003;**5**:659-67.
- 61 Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: Results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). *JACC: Heart Failure* 2013;**1**:308-14.
- 62 Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. *Circulation* 1997;**96**:856-63.
- 63 Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the

Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. *Journal of the American College of Cardiology* 2004;**43**:1423-9.

64 White M, Desai RV, Guichard JL, et al. Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST. *The Canadian journal of cardiology* 2012;**28**:354-9.

65 Dargie HJ, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. *Lancet (London, England)* 1999;**353**:9-13.

66 Phillips SM, Marton RL, Tofler GH. Barriers to diagnosing and managing heart failure in primary care. *The Medical journal of Australia* 2004;**181**:78-81.

67 Hickling JA, Nazareth I, Rogers S. The barriers to effective management of heart failure in general practice. *The British journal of general practice : the journal of the Royal College of General Practitioners* 2001;**51**:615-8.

68 Rossignol P, Zannad F, Pitt B. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. *International journal of cardiology* 2014;**177**:731-3.

69 Lewis EF, Lamas GA, O'Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. *European journal of heart failure* 2007;**9**:83-91.

70 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension (Dallas, Tex : 1979)* 2017.

- 71 Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. *The New England journal of medicine* 2015;**373**:2314-24.
- 72 MacMahon S. Multimorbidity: a priority for global health research. London, UK: Academy of Medical Sciences 2018.
- 73 Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. *PLoS medicine* 2018;**15**:e1002541.
- 74 Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. *Journal of the American College of Cardiology* 2003;**42**:1226-33.
- 75 Lawson CA, Solis-Trapala I, Dahlstrom U, et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. *PLoS medicine* 2018;**15**:e1002540.
- 76 Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. *Journal of the American College of Cardiology* 2014;**64**:2281-93.
- 77 van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. *European journal of heart failure* 2014;**16**:103-11.
- 78 Chamberlain AM, St Sauver JL, Gerber Y, et al. Multimorbidity in heart failure: a community perspective. *Am J Med* 2015;**128**:38-45.
- 79 Henkel DM, Redfield MM, Weston SA, et al. Death in heart failure: a community perspective. *Circulation Heart failure* 2008;**1**:91-7.

- 80 Bromfield SG, Ngameni CA, Colantonio LD, et al. Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With Hypertension. *Hypertension (Dallas, Tex : 1979)* 2017;**70**:259-66.
- 81 Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. *Archives of internal medicine* 2012;**172**:1739-44.
- 82 Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet (London, England)* 2016;**387**:435-43.
- 83 Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet (London, England)* 2016;**387**:957-67.
- 84 Emdin CA, Anderson SG, Woodward M, et al. Usual Blood Pressure and Risk of New-Onset Diabetes: Evidence From 4.1 Million Adults and a Meta-Analysis of Prospective Studies. *Journal of the American College of Cardiology* 2015;**66**:1552-62.
- 85 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet (London, England)* 2007;**369**:201-7.
- 86 Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *The New England journal of medicine* 2008;**358**:1887-98.
- 87 Briasoulis A, Agarwal V, Tousoulis D, et al. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. *Heart (British Cardiac Society)* 2014;**100**:317-23.
- 88 Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ (Clinical research ed)* 2008;**336**:1121-3.

- 89 Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. *BMC medicine* 2015;**13**:78.
- 90 Garrison SR, Kolber MR, Korownyk CS, et al. Blood pressure targets for hypertension in older adults. *The Cochrane database of systematic reviews* 2017;**8**:Cd011575.
- 91 Weiss J, Freeman M, Low A, et al. Benefits and Harms of Intensive Blood Pressure Treatment in Adults Aged 60 Years or Older: A Systematic Review and Meta-analysis. *Ann Intern Med* 2017;**166**:419-29.
- 92 Berlowitz DR, Foy CG, Kazis LE, et al. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. *The New England journal of medicine* 2017;**377**:733-44.
- 93 Odden MC, Peralta CA, Berlowitz DR, et al. Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial. *JAMA internal medicine* 2017;**177**:500-7.
- 94 Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. *Archives of internal medicine* 2003;**163**:1069-75.
- 95 Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *The Lancet Neurology* 2008;**7**:683-9.
- 96 Williamson JD. SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND): preliminary findings. *Alzheimer's Association International Conference (AAIC)*. Chicago, USA 2018.

- 97 Kingston A, Robinson L, Booth H, et al. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. *Age and ageing* 2018;**47**:374-80.
- 98 Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. *Hypertension (Dallas, Tex : 1979)* 2016;**67**:820-5.
- 99 Kjeldsen SE, Stenehjem A, Os I, et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. *Blood Press* 2016;**25**:333-6.
- 100 Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. *Lancet (London, England)* 2015;**385**:2107-17.
- 101 Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *Jama* 2004;**292**:2227-36.
- 102 Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. *Circulation* 2018;**137**:119-29.
- 103 Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *The New England journal of medicine* 2017;**377**:644-57.
- 104 Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. *Journal of hypertension* 2017;**35**:922-44.

- 105 Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. *Kidney Int* 2011;**80**:282-7.
- 106 Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. *Kidney Int* 1997;**51**:793-7.
- 107 Zhang WR, Craven TE, Malhotra R, et al. Kidney damage biomarkers and incident chronic kidney disease during blood pressure reduction: A case-control study. *Ann Intern Med* 2018.
- 108 Nadkarni GN, Chauhan K, Rao V, et al. Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants. *American journal of kidney diseases : the official journal of the National Kidney Foundation* 2018.
- 109 Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. *European journal of heart failure* 2014;**16**:41-8.
- 110 Wilcox CS. New insights into diuretic use in patients with chronic renal disease. *Journal of the American Society of Nephrology : JASN* 2002;**13**:798-805.
- 111 Izzo JL, Jr., Tobe SW. Is there a preferred diuretic class for patients with renal impairment and hypertension? *Journal of the American Society of Hypertension : JASH* 2016;**10**:282-4.
- 112 Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. *Ann Intern Med* 2011;**154**:541-8.

- 113 Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann Intern Med* 2003;**139**:244-52.
- 114 Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. *Journal of the American College of Cardiology* 2014;**64**:588-97.
- 115 Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation* 2003;**107**:2920-5.
- 116 Emdin CA, Callender T, Cao J, et al. Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2015;**17**:701-10.
- 117 Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. *Journal of the American College of Cardiology* 2010;**55**:2299-307.
- 118 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2016;**18**:1609-78.
- 119 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the

Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension (Dallas, Tex : 1979)* 2018;**71**:e13-e115.

120 Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology* 2013;**62**:e147-239.

121 Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Journal of the American College of Cardiology* 2017;**70**:776-803.

122 Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002;**106**:2194-9.

123 Investigators S, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *New England Journal of Medicine* 1991;**325**:293-302.

124 Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet (London, England)* 1999;**353**:2001-7.

125 Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *New England Journal of Medicine* 2001;**345**:1667-75.

- 126 Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *The New England journal of medicine* 2004;**351**:2049-57.
- 127 Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;**362**:772-6.
- 128 McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *The New England journal of medicine* 2014;**371**:993-1004.
- 129 Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial. *Circulation* 1996;**94**:2793-9.
- 130 Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *European heart journal* 2006;**27**:2338-45.
- 131 Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *New England Journal of Medicine* 2008;**359**:2456-67.
- 132 Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *New England Journal of Medicine* 2014;**370**:1383-92.
- 133 Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet (London, England)* 2003;**362**:777-81.
- 134 Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *European heart journal* 2005;**26**:215-25.

- 135 Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009. *Drugs Aging* 2015;**32**:927-36.
- 136 Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥ 75 Years: A Randomized Clinical Trial. *Jama* 2016;**315**:2673-82.
- 137 Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *The New England journal of medicine* 2012;**367**:2204-13.
- 138 Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *European heart journal* 2014;**35**:2797-815.
- 139 Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. *Jama* 2000;**283**:1967-75.
- 140 Bayliss J, Norell MS, Canepa-Anson R, et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. *British medical journal (Clinical research ed)* 1985;**290**:1861-5.